Source: Journal of Clinical Oncology. Conference titles: Annual Meeting of the American Society of Clinical Oncology. Unidade: FM
Subjects: ESTUDOS RETROSPECTIVOS, NEOPLASIAS (DIAGNÓSTICO;QUIMIOTERAPIA), SARCOMA (QUIMIOTERAPIA), ESTADIAMENTO DE NEOPLASIAS, QUIMIOTERAPIA
ABNT
ALMEIDA, G. F et al. Ifosfamide (IFO) and doxorubicin (DOX) dose-intensities seem related to overall survival in adult soft-tissur sarcoma (STS) patients. Journal of Clinical Oncology. Alexandria, VA: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 27 abr. 2024. , 2006APA
Almeida, G. F., Castro Junior, G., Snitcovsky, I. M., Bassani, A. C., Diz, M. E., & Federico, M. H. H. (2006). Ifosfamide (IFO) and doxorubicin (DOX) dose-intensities seem related to overall survival in adult soft-tissur sarcoma (STS) patients. Journal of Clinical Oncology. Alexandria, VA: Faculdade de Medicina, Universidade de São Paulo.NLM
Almeida GF, Castro Junior G, Snitcovsky IM, Bassani AC, Diz ME, Federico MHH. Ifosfamide (IFO) and doxorubicin (DOX) dose-intensities seem related to overall survival in adult soft-tissur sarcoma (STS) patients. Journal of Clinical Oncology. 2006 ; 24( 18S ): 540s.[citado 2024 abr. 27 ]Vancouver
Almeida GF, Castro Junior G, Snitcovsky IM, Bassani AC, Diz ME, Federico MHH. Ifosfamide (IFO) and doxorubicin (DOX) dose-intensities seem related to overall survival in adult soft-tissur sarcoma (STS) patients. Journal of Clinical Oncology. 2006 ; 24( 18S ): 540s.[citado 2024 abr. 27 ]